AZD9291DA HCl salt - CAS 1421372-66-8
Catalog number:
B0084-462681
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C25H31N7O
Molecular Weight:
445.571
COA:
Inquire
Targets:
EGFR
Description:
AZD9291-DA is a des acryl analogue of AZD9291, which is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors. AZD9291 is highly active in preclinical models and is well tolerated in animal models.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-462681 10 mg $399 In stock
Bulk Inquiry
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
third-generation EGFR inhibitor, the potential treatment of advanced lung cancers
Purity:
0.98
Appearance:
brown solid powder
Synonyms:
AZD9291-Des acryl analogue; AZD9291 Des acryl precursor; Mutated EGFR-IN-1; N1-(2-(dimethylamino)ethyl)-5-methoxy-N1-methyl-N4-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)benzene-1,2,4-triamine; N1-(2-dimethylaminoethyl)-5-methoxy-N1-methyl-N4-[4-(1-methylindol-3-yl)pyrimidin-2-yl]benzene-1,2,4-triamine; SCHEMBL14660679
MSDS:
Inquire
Application:
For research used only
InChIKey:
HTNTZPBKKCORTP-UHFFFAOYSA-N
InChI:
InChI=1S/C25H31N7O/c1-30(2)12-13-31(3)23-15-24(33-5)21(14-19(23)26)29-25-27-11-10-20(28-25)18-16-32(4)22-9-7-6-8-17(18)22/h6-11,14-16H,12-13,26H2,1-5H3,(H,27,28,29)
Canonical SMILES:
CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)N)N(C)CCN(C)C)OC
Current Developer:
AstraZenca
1.Hygroscopic growth of water-soluble matter extracted from remote marine aerosols over the western North Pacific: Influence of pollutants transported from East Asia.
Boreddy SK1, Kawamura K2. Sci Total Environ. 2016 Mar 23;557-558:285-295. doi: 10.1016/j.scitotenv.2016.03.096. [Epub ahead of print]
We examined the hygroscopic properties of water-soluble matter (WSM) nebulized from water extracts of total suspended particles (TSP) collected at Chichijima Island in the western North Pacific during January to September 2003. The hygroscopic growth factor g(RH) of the aerosol particles was measured using a hygroscopic tandem differential mobility analyzer (HTDMA) with an initial dry particle diameter of 100nm and relative humidity (RH) of 5-95%. The measured growth factor at 90% RH, g(90%), ranged from 1.51 to 2.14 (mean: 1.76±0.15), significantly lower than that of sea salts (2.1), probably owing to the heterogeneous reactions associated with chloride depletion in sea-salt particles and water-soluble organic matter (WSOM). The g(90%) maximized in summer and minimized in spring. The decrease in spring was most likely explained by the formation of less hygroscopic salts or particles via organometallic reactions during the long-range transport of Asian dust.
2.A hydrometallurgical process for recovering total metal values from waste monolithic ceramic capacitors.
Prabaharan G1, Barik SP2, Kumar B1. Waste Manag. 2016 Apr 12. pii: S0956-053X(16)30173-8. doi: 10.1016/j.wasman.2016.04.010. [Epub ahead of print]
A hydrometallurgical process for recovering the total metal values from waste monolithic ceramic capacitors was investigated. The process parameters such as time, temperature, acid concentration, hydrogen peroxide concentration and other reagents (amount of zinc dust and sodium formate) were optimized. Base metals such as Ba, Ti, Sn, Cu and Ni are leached out in two stages using HCl in stage 1 and HCl with H2O2 in stage 2. More than 99% of leaching efficiency for base metals (Cu, Ni, Ba, Ti and Sn) was achieved. Precious metals such as Au and Pd are leached out using aquaregia and nitric acid was used for the leaching of Ag. Base metals (Ba, Ti, Sn, Cu and Ni) are recovered by selective precipitation using H2SO4 and NaOH solution. In case of precious metals, Au and Pd from the leach solution were precipitated out using sodium metabisulphite and sodium formate, respectively. Sodium chloride was used for the precipitation of Ag from leach solution.
3.Characterizing the Dissolution Profiles of Supersaturable Salts, Cocrystals, and Solvates to Enhance In Vivo Oral Absorption.
Hisada N1, Takano R1, Takata N1, Shiraki K1, Ueto T1, Tanida S1, Kataoka M2, Yamashita S3. Eur J Pharm Biopharm. 2016 Apr 6. pii: S0939-6411(16)30128-X. doi: 10.1016/j.ejpb.2016.04.004. [Epub ahead of print]
The purposes of this study were to elucidate the type-specific characteristics of salt, cocrystal, and solvate formulations upon dissolution and precipitation, and to clarify their effect on enhancing oral absorption. Several types of solid formulations (dantrolene sodium salt [DAN-NA], pioglitazone hydrochloride salt [PIO-HCL], megestrol acetate saccharin cocrystal [MEG-SA], and an in-house compound ZR ethanolate [ZR-ETH]) that induce supersaturation of BCS class II drugs were compared to their crystalline free forms. An in vitro miniscale dissolution test in biorelevant media was used to characterize their dissolution profiles and residue forms. Both salts (DAN-NA and PIO-HCL) rapidly reached the maximum concentration within 5 minutes, whereas the cocrystal (MEG-SA) did so slowly. After the maximum concentration had been reached, the dissolved concentrations of DAN-NA, PIO-HCL, and MEG-SA decreased, but that of ZR-ETH did not. Time-dependent XRPD analysis revealed that the initial solid state of each salt dissolved within 5 minutes, whereas the cocrystal remained for more than 10 minutes, and the solvate remained for 4 hours.
4.Improving the yield of (+)-terrein from the salt-tolerant Aspergillus terreus PT06-2.
Zhao C1, Guo L1, Wang L2, Zhu G1, Zhu W3. World J Microbiol Biotechnol. 2016 May;32(5):77. doi: 10.1007/s11274-016-2029-0. Epub 2016 Apr 2.
(+)-Terrein has a potential application for drug discovery. To improve the yield of (+)-terrein, two-level Plackett-Burman design and response surface methodology methods were used to optimize the condition of a salt-tolerant fungus, Aspergillus terreus PT06-2. As a result, the yield of (+)-terrein reached 8.20 ± 0.072 g/L in a 500-mL flask containing 150 mL optimal medium consisted of 13.1 % NaCl, 3.6 % starch, 2 % sodium glutamate, 0.05 % KCl, 3 % inoculum size, adjusting initial pH value to 5 with 10 % HCl and shaking for 18 days at 28 °C and 180 rpm. The production of (+)-terrein was 47.0 % higher than the highest production reported in shake flasks. The advantages of this optimization are uses of single carbon source and nitrogen source and easy separation and purification by recrystallization. The result exhibited the potential and advantages of A. terreus PT06-2 in industrial production of (+)-terrein by fermentation.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related EGFR Products


TPC-064

TPC-064 is a novel mutant-selective inhibitor of EGFR, which plays a role in NSCLC and therefore becomes a key target for cancer therapy. TPC-064 can selectivel...

CAS 1204313-51-8 Icotinib (Hydrochloride)

Icotinib (Hydrochloride)
(CAS: 1204313-51-8)

CAS 714971-09-2 AC480

AC480
(CAS: 714971-09-2)

AC480, also known as BMS-599626, is an orally bioavailable inhibitor of the HER1, HER2 and HER4 tyrosine kinases (IC50 =22, 32 and 190 nM, respectively) with po...

EAI045
(CAS: 1942114-09-1)

EAI045 is an allosteric, non-ATP competitive inhibitor of mutant EGFR. In vitro studies proved that EAI045 is active and selective for T790M- harboring EGFR mut...

AZD3759
(CAS: 1626387-80-1)

AZD3759 is a n orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, AZD3...

AZ5104
(CAS: 1421373-98-9)

AZ5104, the demethylated metabolite of AZD-9291, is a potent EGFR inhibitor with IC50 of

MTX-211
(CAS: 1952236-05-3)

MTX-211 is a dual inhibitor of EGFR and PI3K, which plays important roles in the progression of KRAS mutant colorectal cancer. MTX-211 has the potential for the...

CAS 451493-31-5 AV-412 Tosylate

AV-412 Tosylate
(CAS: 451493-31-5)

AV-412 is a dual EGFR/ErbB2 kinase inhibitor. It completely inhibits the tumor growth of both H1650 and H1975 xenografts in nude mice. It is proved that AV-412 ...

CAS 1374640-70-6 CO1686

CO1686
(CAS: 1374640-70-6)

BGB-283
(CAS: 1446090-77-2)

BGB-283 is a selective Epidermal growth factor receptor and Proto oncogene protein b raf inhibitor under the development of BeiGene. BGB-283 shows antitumor act...

CAS 1421373-66-1 AZD-9291 mesylate

AZD-9291 mesylate
(CAS: 1421373-66-1)

AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become ...

CGP-59326
(CAS: 173458-56-5)

CGP-59326, a pyrrolopyrimidine derivative, has been found to be an EGFR antagonist and could used in antineoplastic studies.

PF-06459988
(CAS: 1428774-45-1)

PF-06459988 is a third-generation, irreversible epidermal growth factor receptor (EGFR) inhibitor. It can bind to and inhibit mutant forms of EGFR, including th...

CAS 183322-45-4 PD153035 HCl

PD153035 HCl
(CAS: 183322-45-4)

PD153035 is a potent and specific inhibitor of EGFR with Ki and IC50 of 5.2 pM and 29 pM; little effect noted against PGDFR, FGFR, CSF-1, InsR and Src.

Naquotinib
(CAS: 1448232-80-1)

Naquotinib is a irreversible, third-generation, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activitywith ...

CAS 871026-44-7 TAK-285

TAK-285
(CAS: 871026-44-7)

TAK-285 is a novel dual erbB protein kinase inhibitor that specifically targets human epidermal growth factor receptor (EGFR) and HER2. Methods: TAK-285 is curr...

CAS 133550-41-1 AG 556

AG 556
(CAS: 133550-41-1)

AG 556, a dihydroxyphen derivative, has been found to be a EGFR kinase inhibitor that could probably be effective in the study of myocardial infarct and hemodyn...

CAS 897383-62-9 AST-1306

AST-1306
(CAS: 897383-62-9)

AST-1306 functions as an irreversible inhibitor, most likely through covalent interaction with Cys797 and Cys805 in the catalytic domains of EGFR and ErbB2, res...

CAS 136831-48-6 RG13022

RG13022
(CAS: 136831-48-6)

RG13022, a non-phenolic tyrphostin analog, is an epidermal growth factor (EGF) receptor tyrosine kinase inhibitor with potential antiproliferative effect.

CAS 366017-09-6 Mubritinib

Mubritinib
(CAS: 366017-09-6)

Mubritinib, also known as TAK-165, is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer. It completed phase I clinic...

Chemical Structure

CAS 1421372-66-8 AZD9291DA HCl salt

Quick Inquiry

Verification code

Featured Items